DiaGenic installs state-of-the-art qPCR technology from Life Technologies Corporation
DiaGenic announces that it has made an investment in the latest technology for analyzing gene expression in blood. The deployment of QuantStudio™ Dx instruments from Life Technologies in the company’s central laboratory will further enhance the regulatory approvability and future clinical utility of DiaGenic’s products in development.
DiaGenic’s diagnostic products are based on a laboratory technique called quantitative real time polymerase chain reaction (qPCR), which is used to amplify and simultaneously quantify targeted DNA molecules. Diseases, including Alzheimer’s disease, give rise to unique gene expression profiles that can be detected using qPCR technology. DiaGenic use proprietary sets of genes and transform the gene expression profile into a simple and convenient diagnostic test requiring only a blood sample from the patient.
Life Technologies launched its flagship qPCR instrument QuantStudio™ Dx in November 2012. The instrument is CE-IVD marked for use in Europe and received a 510(k) clearance from the United States Food and Drug Administration (FDA) in March this year to market an assay for Clostridium difficile bacterial infections.
“The clinical utility and market acceptance of DiaGenic’s diagnostic products in development will benefit from being validated using state of the art technology and an instrument that is approved by regulatory agencies in major markets. We are pleased to have a good and long standing working relationship with Life Technologies,” said Paul de Potocki, CEO at DiaGenic.
"Molecular diagnostic tests based on real-time PCR have become indispensable to the clinical lab," said Ronnie Andrews, president of Medical Sciences at Life Technologies. "Molecular testing is the fastest-growing segment of the diagnostics market. We are pleased to work with DiaGenic as part of a broad partnership base in the diagnostic and pharmaceutical space to develop content and products that may play an increasingly important role in the clinic."
For more information, contact:
Paul de Potocki, CEO at DiaGenic, telephone: +47 2324 8950
Magnus Sjögren, Chief Medical Officer at DiaGenic, telephone: +47 2324 8950
About DiaGenic ASA
DiaGenic is an innovative diagnostic company that seeks to create value for patients, partners and investors by developing patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange.